A clinical trial testing AzurRx BioPharma‘s investigational therapy MS1819, in combination with the current standard care for the…
Articles by Marisa Wexler, MS
The Cystic Fibrosis Foundation (CFF) has awarded up to $3.3 million to Polyphor AG to advance the testing…
AzurRx BioPharma is requesting a new patient arm be added to its ongoing Phase 2b trial investigating MS1819 capsules as a…
The European Commission has approved Kalydeco (ivacaftor), by Vertex Pharmaceuticals, to treat infants as young as four months…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of…
Oral lenabasum failed to significantly reduce the frequency of pulmonary exacerbations in people with cystic fibrosis (CF) treated in…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…
A Phase 2 clinical trial of oral lenabasum in people with cystic fibrosis (CF) failed to meet its primary goal of…
Oral antibiotics are just as effective as intravenous (into-the-vein) antibiotics at killing Pseudomonas aeruginosa bacteria in people with…
The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals‘ Kalydeco (ivacaftor) as a treatment…